Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan/HDS and Trifluridine-Tipiracil + Bevacizumab in Refractory Metastatic Colorectal Cancer
NCT06607458Phase 2Recruiting
- Sponsor
- Delcath Systems
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of melphalan in metastatic colorectal cancer (mCRC), sponsored by Delcath Systems. Started Aug 2025; status: recruiting.
02
Drugs
melphalan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06607458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607458.